SYVN1 and urinary bladder carcinoma: Mechanistic studies have unveiled that circSIRT5 exerts its anticancer effects by forming a circSIRT5/SYVN1/PHGDH ternary complex, thereby facilitating the ubiquitination and degradation of PHGDH, ultimately promoting ferroptosis in bladder cancer cells and subsequently exhibiting its antitumor activity.